HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Piramal Pharma Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 55 filings·Updated 1 Oct 2026
Showing 10 of 55 filings.
1 Oct 20261 filing
Company UpdateNews Verification

The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharmas Aurora Facility.. The response from the Company is attached.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 19:14View Source
30 Sept 20263 filings
Company UpdateNews Verification

The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharmas Aurora Facility.. The response from the Company is awaited.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 17:56View Source
Company UpdateChange in Management

Brian Guy appointed President & COO of Piramal Critical Care after Jeffrey Hampton retirement

Senior Management Change

  • Mr. Jeffrey Hampton will retire as President and COO, Piramal Critical Care, effective 27 November 2026.
  • Board approved Brian Guy as President and COO, Piramal Critical Care, SMP, effective 19 October 2026.
  • Appointment follows retirement of Jeffrey Hampton, with the change approved by the Nomination and Remuneration Committee.
  • Brian Guy is not related to any Director of the Company.
  • Brian Guy profile: over 25 years in pharma; currently President & CCO at Breckenridge Pharmaceutical.
Filed 17:55View Source
Company UpdateClarification

The Exchange has sought Clarification from Piramal Pharma Ltd with reference to the media report appearing on https://www.thehindubusinessline.com/ dated September 30, 2026 (Link: https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece) ....

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 17:53
29 Sept 20262 filings
Insider Trading / SASTClosure of Trading Window

Piramal Pharma Limited trading window closed from Oct 1, 2026 until 48 hours after declaration of unaudited half-year results for the six months ending Sep 30, 2026

Piramal Pharma Limited trading window closed from Oct 1, 2026 until 48 hours after declaration of unaudited half-year results for the six months ending Sep 30, 2026

Filed 11:10View Source
Company UpdatePendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Piramal Pharma GST ITC Demand of Rs 4,06,03,220; Appeal Planned

GST ITC Order

  • Order received on 28 September 2026; ITC includes post-demerger period, ISD credits, overseas cross-charges by Piramal Enterprises.
  • Demand of ITC Rs 4,06,03,220 with interest and equal penalty; company to appeal.
Filed 10:58View Source
18 Sept 20261 filing
Company UpdateGeneral

External ESG rating of 67.1 (Leader) assigned to Piramal Pharma by Niche99.

ESG rating

  • ESG rating 67.1 (Leader) awarded; date Sept 17, 2026.
  • Rating prepared by Niche99 independently from public data; not engaged by Piramal Pharma.
  • Disclosure is informational; no direct impact on operations or strategy.
Filed 19:39View Source
14 Sept 20261 filing
Company UpdateGeneral

US FDA GMP inspection at Piramal Morpeth facility yields Form-483 with seven observations; response being prepared

FDA inspection update

  • US FDA GMP inspection of Morpeth, UK facility conducted Sep 3–11, 2026, with Form-483 issued listing seven observations.
  • Company is diligently addressing observations and preparing a detailed response within the regulatory timeline.
  • Observations relate to enhancements in practices, procedures and documentation.
  • Company remains committed to addressing all observations in collaboration with the FDA.
Filed 19:50View Source
8 Sept 20261 filing
Company UpdateAnalyst / Investor Meet

Piramal Pharma Announces Avendus-Organized Institutional Investor Meetings in the UK on Sept 29–30, 2026

Meeting Details

  • Dates: 29–30 September 2026; times not specified; physical meetings in the United Kingdom.
  • Nature: Group / One-on-one meetings.
  • Organised by Avendus Spark Institutional Equities.

Participants

  • Expected company management participants; specific roles not disclosed.

Purpose

  • Purpose: schedule institutional investor meetings; investor interaction.
Filed 15:33View Source
3 Sept 20261 filing
Company UpdateGeneral

Piramal Pharma ESG rating improves to 65 for FY2025-26; rating prepared by NSE Sustainability without company engagement

ESG rating update

  • NSE Sustainability assigned an ESG rating of 65 for FY2025-26, up from 64.
  • Company notes it did not engage NSE Sustainability; rating prepared from public-domain data.
  • Intimation uploaded on Piramal Pharma's website.
Filed 14:28View Source
Showing 10 of 55 filings